p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy.

Standard

p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. / Shariat, Shahrokh F; Lotan, Yair; Karakiewicz, Pierre I; Ashfaq, Raheela; Isbarn, Hendrik; Fradet, Yves; Bastian, Patrick J; Nielsen, Matthew E; Capitanio, Umberto; Jeldres, Claudio; Montorsi, Francesco; Müller, Stefan C; Karam, Jose A; Heukamp, Lukas C; Netto, George; Lerner, Seth P; Sagalowsky, Arthur I; Cote, Richard J.

in: J UROLOGY, 2009.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Shariat, SF, Lotan, Y, Karakiewicz, PI, Ashfaq, R, Isbarn, H, Fradet, Y, Bastian, PJ, Nielsen, ME, Capitanio, U, Jeldres, C, Montorsi, F, Müller, SC, Karam, JA, Heukamp, LC, Netto, G, Lerner, SP, Sagalowsky, AI & Cote, RJ 2009, 'p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy.', J UROLOGY. <http://www.ncbi.nlm.nih.gov/pubmed/19616250?dopt=Citation>

APA

Shariat, S. F., Lotan, Y., Karakiewicz, P. I., Ashfaq, R., Isbarn, H., Fradet, Y., Bastian, P. J., Nielsen, M. E., Capitanio, U., Jeldres, C., Montorsi, F., Müller, S. C., Karam, J. A., Heukamp, L. C., Netto, G., Lerner, S. P., Sagalowsky, A. I., & Cote, R. J. (2009). p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. J UROLOGY. http://www.ncbi.nlm.nih.gov/pubmed/19616250?dopt=Citation

Vancouver

Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y et al. p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. J UROLOGY. 2009.

Bibtex

@article{c930b21586e24c288311c00fecddfa71,
title = "p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy.",
abstract = "PURPOSE: Approximately 15% to 30% of patients with pT1-2N0M0 urothelial carcinoma of the bladder experience disease progression despite radical cystectomy with curative intent. We determined whether p53 expression would improve the prediction of disease progression after radical cystectomy for pT1-2N0M0 UCB. MATERIALS AND METHODS: In a multi-institutional retrospective cohort we identified 324 patients with pT1-2N0M0 urothelial carcinoma of the bladder who underwent radical cystectomy. Analysis focused on a testing cohort of 272 patients and an external validation of 52. Competing risks regression models were used to test the association of variables with cancer specific mortality after accounting for nonbladder cancer caused mortality. RESULTS: In the testing cohort 91 patients (33.5%) had altered p53 expression (p53alt). On multivariate competing risks regression analysis altered p53 achieved independent status for predicting disease recurrence and cancer specific mortality (each p",
author = "Shariat, {Shahrokh F} and Yair Lotan and Karakiewicz, {Pierre I} and Raheela Ashfaq and Hendrik Isbarn and Yves Fradet and Bastian, {Patrick J} and Nielsen, {Matthew E} and Umberto Capitanio and Claudio Jeldres and Francesco Montorsi and M{\"u}ller, {Stefan C} and Karam, {Jose A} and Heukamp, {Lukas C} and George Netto and Lerner, {Seth P} and Sagalowsky, {Arthur I} and Cote, {Richard J}",
year = "2009",
language = "Deutsch",
journal = "J UROLOGY",
issn = "0022-5347",
publisher = "Elsevier Inc.",

}

RIS

TY - JOUR

T1 - p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy.

AU - Shariat, Shahrokh F

AU - Lotan, Yair

AU - Karakiewicz, Pierre I

AU - Ashfaq, Raheela

AU - Isbarn, Hendrik

AU - Fradet, Yves

AU - Bastian, Patrick J

AU - Nielsen, Matthew E

AU - Capitanio, Umberto

AU - Jeldres, Claudio

AU - Montorsi, Francesco

AU - Müller, Stefan C

AU - Karam, Jose A

AU - Heukamp, Lukas C

AU - Netto, George

AU - Lerner, Seth P

AU - Sagalowsky, Arthur I

AU - Cote, Richard J

PY - 2009

Y1 - 2009

N2 - PURPOSE: Approximately 15% to 30% of patients with pT1-2N0M0 urothelial carcinoma of the bladder experience disease progression despite radical cystectomy with curative intent. We determined whether p53 expression would improve the prediction of disease progression after radical cystectomy for pT1-2N0M0 UCB. MATERIALS AND METHODS: In a multi-institutional retrospective cohort we identified 324 patients with pT1-2N0M0 urothelial carcinoma of the bladder who underwent radical cystectomy. Analysis focused on a testing cohort of 272 patients and an external validation of 52. Competing risks regression models were used to test the association of variables with cancer specific mortality after accounting for nonbladder cancer caused mortality. RESULTS: In the testing cohort 91 patients (33.5%) had altered p53 expression (p53alt). On multivariate competing risks regression analysis altered p53 achieved independent status for predicting disease recurrence and cancer specific mortality (each p

AB - PURPOSE: Approximately 15% to 30% of patients with pT1-2N0M0 urothelial carcinoma of the bladder experience disease progression despite radical cystectomy with curative intent. We determined whether p53 expression would improve the prediction of disease progression after radical cystectomy for pT1-2N0M0 UCB. MATERIALS AND METHODS: In a multi-institutional retrospective cohort we identified 324 patients with pT1-2N0M0 urothelial carcinoma of the bladder who underwent radical cystectomy. Analysis focused on a testing cohort of 272 patients and an external validation of 52. Competing risks regression models were used to test the association of variables with cancer specific mortality after accounting for nonbladder cancer caused mortality. RESULTS: In the testing cohort 91 patients (33.5%) had altered p53 expression (p53alt). On multivariate competing risks regression analysis altered p53 achieved independent status for predicting disease recurrence and cancer specific mortality (each p

M3 - SCORING: Zeitschriftenaufsatz

JO - J UROLOGY

JF - J UROLOGY

SN - 0022-5347

ER -